Fluoropyrimidine-related AEs greater in women
- PDF / 169,962 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 24 Downloads / 229 Views
1
Fluoropyrimidine-related AEs greater in women The risk and severity of fluoropyrimidine-related adverse events (AEs) in patients with colon cancer appear to be greater in women than in men, according to findings of a study published in the Journal of the National Cancer Institute. Logistic regression analysis of data from the international ACCENT (Adjuvant Colon Cancer End Points) database was used to investigate the risk and severity of fluoropyrimidine-related AEs in 34 640 patients with colon cancer receiving fluoropyrimidine (fluourouracil [5-FU] or capecitabine)-based adjuvant chemotherapy, with or without oxaliplatin. Grade III/IV AEs with significantly greater odds in women versus men (all p
Data Loading...
